• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥沙利铂所致过敏反应的临床特征:一项回顾性多中心分析。

Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis.

机构信息

Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Hubei Center for Adverse Drug Reaction Monitoring, Wuhan, 430030, China.

出版信息

Curr Med Sci. 2021 Aug;41(4):827-831. doi: 10.1007/s11596-021-2387-1. Epub 2021 Aug 17.

DOI:10.1007/s11596-021-2387-1
PMID:34403109
Abstract

OBJECTIVE

The characteristics of oxaliplatin-induced hypersensitivity reactions (HSRs) in Chinese patients were investigated to provide a reference for patients treated with oxaliplatin.

METHODS

The study reviewed the records of patients who developed oxaliplatin-induced HSRs in 17 hospitals from May 2016 to May 2017. We collected and analyzed the basic information, history of oxaliplatin administration and premedication treatments, chemotherapy cycles, HSR symptoms, and the management and outcomes of these patients.

RESULTS

Oxaliplatin-induced HSRs were recorded in 137 patients who had been treated with oxaliplatin-containing regimens. Five different chemotherapy regimens were applied. The median infusion cycle when oxaliplatin-induced HSRs occurred was 7, and HSRs occurred during or shortly after oxaliplatin infusion. Most of the patients experienced grade 1 or grade 2 HSRs with mild symptoms of pruritis (49.64%), flushing (46.72%), chest discomfort (26.28%), and urticaria (25.55%). The majority of the patients completely recovered from HSRs following treatment with antihistamines and dexamethasone. Seven patients completed chemotherapy with oxaliplatin after the symptoms resolved with proper management.

CONCLUSION

The results indicate that oxaliplatin-induced HSRs remain an important issue in safely and successfully fulfilling oxaliplatin-containing chemotherapy. Further studies are needed to analyze the risk factors and establish prophylaxis for such reactions.

摘要

目的

研究中国患者奥沙利铂诱导的过敏反应(HSR)的特征,为奥沙利铂治疗患者提供参考。

方法

本研究回顾了 2016 年 5 月至 2017 年 5 月 17 家医院接受奥沙利铂诱导 HSR 的患者的记录。我们收集并分析了患者的基本信息、奥沙利铂给药和预处理治疗史、化疗周期、HSR 症状以及这些患者的治疗和结局。

结果

137 例接受含奥沙利铂方案治疗的患者记录了奥沙利铂诱导的 HSR。应用了五种不同的化疗方案。发生奥沙利铂诱导的 HSR 时的中位输注周期为 7,HSR 发生在奥沙利铂输注期间或输注后不久。大多数患者出现 1 级或 2 级 HSR,症状轻微,表现为瘙痒(49.64%)、潮红(46.72%)、胸部不适(26.28%)和荨麻疹(25.55%)。大多数患者在接受抗组胺药和地塞米松治疗后完全从 HSR 中恢复。7 例患者在症状缓解后完成了奥沙利铂化疗。

结论

结果表明,奥沙利铂诱导的 HSR 仍然是安全、成功完成含奥沙利铂化疗的重要问题。需要进一步研究分析这些反应的危险因素,并制定预防措施。

相似文献

1
Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis.奥沙利铂所致过敏反应的临床特征:一项回顾性多中心分析。
Curr Med Sci. 2021 Aug;41(4):827-831. doi: 10.1007/s11596-021-2387-1. Epub 2021 Aug 17.
2
Oxaliplatin-induced hypersensitivity reactions: risk factors and management.奥沙利铂诱导的过敏反应:危险因素与管理
Eur Rev Med Pharmacol Sci. 2023 Mar;27(6):2640-2645. doi: 10.26355/eurrev_202303_31801.
3
Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.对奥沙利铂的超敏反应:识别风险因素并评估脱敏方案的疗效
Clin Ther. 2015 Jun 1;37(6):1259-69. doi: 10.1016/j.clinthera.2015.03.012. Epub 2015 Apr 7.
4
Oxaliplatin: Detection and Management of Hypersensitivity Reactions.奥沙利铂:过敏反应的检测与处理
Clin J Oncol Nurs. 2019 Feb 1;23(1):68-75. doi: 10.1188/19.CJON.68-75.
5
Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients.结直肠癌患者奥沙利铂过敏反应的临床分析。
Oncol Res. 2018 Jun 11;26(5):801-807. doi: 10.3727/096504017X15139039328978. Epub 2018 Jan 2.
6
Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.对奥沙利铂的超敏反应:一项回顾性研究及脱敏方案的制定
Clin Colorectal Cancer. 2009 Apr;8(2):106-9.
7
Incidence and Risk of Oxaliplatin-Induced Hypersensitivity in Patients with Asymptomatic Prior Exposure: A Prospective Observational Study.奥沙利铂诱导的无症状既往暴露患者过敏反应的发生率和风险:一项前瞻性观察研究。
J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1642-1648.e2. doi: 10.1016/j.jaip.2017.12.026. Epub 2018 Feb 14.
8
Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.结直肠癌患者对改良FOLFOX6和XELOX治疗周期的超敏反应比较。
Cancer Chemother Pharmacol. 2017 May;79(5):1021-1029. doi: 10.1007/s00280-017-3294-9. Epub 2017 Apr 8.
9
Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity.简化的奥沙利铂过敏缓解分级输注策略。
Clin Colorectal Cancer. 2022 Jun;21(2):149-153. doi: 10.1016/j.clcc.2022.01.006. Epub 2022 Jan 19.
10
Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions.轻度过敏反应后重新引入奥沙利铂治疗结直肠癌患者的临床结局。
Oncology. 2013;85(6):323-7. doi: 10.1159/000355831. Epub 2013 Nov 12.

引用本文的文献

1
Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.结直肠癌患者中奥沙利铂诱导的超敏反应的危险因素。
Am J Transl Res. 2022 Apr 15;14(4):2461-2468. eCollection 2022.
2
Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study.奥沙利铂在中国3687例癌症患者中的安全性概况:一项上市后监测研究。
Front Oncol. 2021 Oct 21;11:757196. doi: 10.3389/fonc.2021.757196. eCollection 2021.

本文引用的文献

1
Skin test protocol for the prevention of hypersensitivity reactions to oxaliplatin.奥沙利铂过敏反应预防的皮肤试验方案。
Anticancer Res. 2014 Jan;34(1):537-40.
2
Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer.成功再挑战奥沙利铂过敏反应的转移性结直肠癌患者。
Anticancer Res. 2012 Dec;32(12):5521-6.
3
Fatal thrombocytopenia after oxaliplatin-based chemotherapy.基于奥沙利铂的化疗后出现致命性血小板减少症。
Anticancer Res. 2008 Sep-Oct;28(5B):3115-7.
4
Anaphylaxis produced by oxaliplatin.奥沙利铂引起的过敏反应。
J Investig Allergol Clin Immunol. 2005;15(1):75-7.